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Syntheses are reported for three analogues of vasopressin in which the C-terminal glycinamide 
moiety has been deleted from the parent hormones. All three analogues have been synthesized by the 
solid-phase method, and purified by gel filtration in two steps. 
Vasopressin and other neurohypophyseal peptides influence memory and learn-
ing processes. Structure-activity studies in the pole-jumping avoidance test revealed 
that arginine-vasopressin (AVP) is the most potent peptide, followed by lysine-vaso-
pressin (LVP) [1, 2]. Removal of the C-terminal glycinamide (dGAVP and dGLVP) 
decreases the potency by approximately 50 per cent [3]. Such peptides have practically 
no classical endocrine activities (e.g. blood pressure, antidiuresis and ACTH 
release) [4]. These findings indicate a dissociation between the endocrine and beha-
vioural effects of neurohypophyseal hormones. DGLVP has been isolated from porcine 
pituitary glands [5]. These results have started a search for vasopressin analogues 
that influence learning and memory, but do not cause water retention as do LVP, 
AVP and some of their analogues. 
In this paper we describe the synthesis of three (9-desglycinamide)-vasopressin 
analoaues. The synthesized analogues are shown in 
Fig. f. 
The peptides were prepared by the general 
stepwise solid-phase method on chloromethylated 
polystyrene resin [6], as applied in the synthesis of 
oxytocin [7, 8]. At the end of the synthesis, the fully 
protected peptides were cleaved by alcoholysis from 
the solid support [9, 10], instead of the rather drastic 
cleavage with HBr/TFA or HF. This resulted in protected peptide esters, which were 
hydrolyzed with NaOH in DMF/pyridine to give protected octapeptides with a 
C-terminal free carboxyl groups. After the hydrolysis racemization was not detected. 
All three protected octapeptides were deblocked with Na in liquid ammonia 
[11], using some modifications as described by MANNING ETAL. [12]. The linear com-
pounds were oxidatively cyclized with aqueous K3[Fe(CN)6] [13]. The cyclized 
analogues were desalted and purified by gel filtration on a Sephadex G-15 column in 
two steps [14]. The schematic synthesis of dGAVP is shown in Fig. 2. 
H - C y s . -Ty r - P h e - G I n - A s n - C y s - I 
H -Cys -Ty r - P h e - G I n - A s n - C y s - I 
H - C y s - T y r - P h e - G I n - Asn -Cys -
Fig. 1 
188 M. TÓTH and HIS COWORKERS 
The final peptides were pure on different TLC systems, and the amino acid com-
positions were confirmed by amino acid analysis. 
The physical data on the three analogues are summarized in Table I. 
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Melting points were determined on a PHMK (VEB Analytik Dresden) apparatus 
and are uncorrected. Optical rotations were measured with a Carl Zeiss polari-
meter (Polamat A). Amino acid analyses were performed using a Czechoslovak 
AAA 881 analyzer. Peptide samples were hydrolyzed during 24 h in 6N HC1 at 110 °C 
in vacuum-sealed tubes. 
Thin-layer chromatography (TLC) was carried out on Merck precoated silica 
gel plates (Kieselgel 60). The following solvent systems were used: A, 1-butanol-
-acetic acid-water (4:1:1, v/v); B, 1-butanol-pyridine-acetic acid-water (30:20:6: 24, 
v/v); C, chloroform-methanol (7:3, v/v). Ninhydrin, TMD and iodine vapour 
were used for detection. Solvents and reagents used for solid-phase synthesis were of 
analytical grade and were distilled immediately prior to use. 
Table I 
Physical data on the synthesized analogues 










Tyr Phe Glu Asp Cys Pro X 
prot. dGAVP-OMe 
(1) 40 1602.9 C81H05O10N13S3 195—197 -36.5° 0.66 0.76 — 
prot. dGAVP-OH (2) 74 1588.9 C8„H83O16N13S3 162—165 -35.4° 0.60 0.64 — 0.78 0.92 1.02 1.08 1.75* 1.01 1.00 
dGAVP (3) 37 1029.1 C14H64OJ2N13S2 — — 0.20 0.49 — 0.80 0.95 1.05 1.10 0.75 1.10 1.00 
prot. dGLVP-OMe 
(4) 30 1574.9 C81H05O10NUS3 210—213 -39.1° 0.71 0.72 0.90 
prot. dGLVP-OH (5) 90 1560.9 CW^OUNNS, 155—157 -40.8° 0.65 0.62 — 0.68 0.90 0.98' 1.00 1.65* 1.07 1.02 
dGLVP (6) 32 1001,1 CHHIMOJÜN!^ — — 0.15 0.45 — 0.76 1.20 1.06 1.00 0.75 1.09 1.06 
prot. dGOVP-OMe 
(7) 67 1560.9 CSOHGSOIßNUSS 197—200 -35.7° 0.71 0.76 0.90 
prot. dGOVP-OH(8) 72 1546.9 C J . H ^ . N J X S , 160—165 -27.2° 0.47 0.63 — 0.72 1.00 0.91 1.08 1.48* 1.20 0.74 
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Z-Cys(Bzl)-Tyr(Bzl)-Phe-Gln-Asn-Cys(Bzl)-Pro-Arg(Tos)-OMe (1) 
The solid-phase synthesis procedure conformed to that described previously [6]. 
1% Chloromethylated resin (Bio Beads Sx-1) was esterified with Boc-Arg(Tos)-OCs 
to an incorporation of0.18 mmol/g resin [15]. 1.8 g Boc-Arg(Tos)-resin (0.32 mmol of 
Arg) was elongated. Seven cycles of deprotection, neutralization and coupling were 
carried out with the following protected amino acid derivatives; Boc-Pro, Boc-
Cys(Bzl), Boc-Asn, Boc-Gln, Boc-Phe, Boc-Tyr(Bzl) and Z-Cys(Bzl) with coupling 
in the final step. All coupling reactions were carried out by DCC in CH2CI2 [16], 
except in the cases of Asn and Gin which reacted as the nitrophenyl ester deriva-
tives [17] in DMF. These couplings being facilitated by the addition of HOBt [18]. 
At the end of the synthesis the protected peptide resin (2.1 g) were washed out 
of the reaction vessel with CH2C12, MeOH, EtaO and dried in vacuo. 
1.97 g of the protected octapeptide-resin was suspended in 25 ml of DMF, 25 ml 
of MeOH and 11 ml of TEA [9, 10]. The mixture was stirred at 45 °C for 24 h. The 
resin was filtered and was washed with warm DMF (2x25 ml). The resin was retrea-
ted by the same procedure for another 24 h, filtered and washed again with DMF 
(2 + 25 ml) and MeOH (25 ml). The filtrates were combined and evaporated in vacuo. 
The oil residue was dissolved in AcOH (4 ml) and the protected octapeptide methyl 
ester was precipitated by the addition of EtOH. The crude product was reprecipi-
tated from DMF-Et0H-Et20 to give (1) (0.197 g). 
Z-Cysf Bzl)-Tyr( Bzl)-Phe-Gln-Asn-Cys( Bzl)-Pro-Arg( Tos)-OH (2) 
150 mg of protected octapeptide-OMe (1) was dissolved in 1 ml of pyridine and 0.5 ml 
of DMF. The pH was adjusted to 9—10 with 1 N NaOH and the mixture was stirred 
for 10 h. The pH was then adjusted to 7 with 1 N HC1 and the protected octapeptide 
was precipitated. Removal of the solvents in vacuo, followed by trituration with 
Et20 and drying in vacuo over P205 , gave the protected octapeptide (2) (llOmg). 
(9-desglycinamide)-arginine-vasopressin (dGAVP) (3) 
The protected octapeptide (2) was deblocked by the sodium-liquid ammonia proce-
dure [8, 13]. 100 mg of (2) was dissolved in 180 ml of boiling NH3, freshly distilled 
over Na. Fresh Na stick was introduced into the solution until a light-blue colour 
persisted for 30 sec, 0.5 ml of acetic acid was added to discharge the colour. The solu-
tion was evaporated and N2 was passed through the flask. The residue was 
dissolved in 50 ml of 20% AcOH and quickly poured into 1000 ml of ice-cold water. 
The pH of the solution was adjusted to 7 with NH4OH, and 0.01 N K3[Fe(CN)6] 
was added with stirring until a yellow colour persisted (12 ml). The yellow solution 
was stirred for further 30 min, and than for 20 min with the anion-exchange resin 
(Ambeilyst A 26 CI ~ form) to remove ferrocyanide and excess ferricyanide ions. The 
resin was removed by filtration and washed with 100 ml of water. The combined 
filtrate and washings were lyophilized. The resulting material was desalted on a 
Sephadex G-15 column (110x2.5 cm), with elution with 50% AcOH at a flow rate 
of 8 ml/h. The eluate was fractionated, and monitored for absorbance at 277 nm. 
The fractions were checked by TLC, pooled and lyophilized, and the residue was 
further desalted by gel filtration on a Sephadex G-15 column (100x1.6 cm), with 
elution with 0.2 N AcOH at a flow rate of 4 ml/h. The peptide was eluted in a single 
peak. The lyophilization of these fractions yielded the pure dGAVP (3) as a white 
powder (24 mg). 
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Z-Cys( Bzl)-Tyr( Bzl)-Phe-Gln-Asn-Cys( Bzl)-Pro-Lys( Tos)-OMe (4) 
4.3 g of the protected octapeptide resin was obtained as described above, using 3.5 g 
Boc-Lys(Tos)-resin containing 0.55 mmol of Boc-Lys(Tos)-OH per g resin. The 
protected octapeptide methyl ester (4) was cleaved from 3 g of the resin in the manner 
detailed above for (1): yield 620 mg of (4). 
Z-Cys( Bzl)-Tyr( Bzl)-Phe-Gln-Asn-Cys( Bzl)-Pro-Lys( Tos)-OH (5) 
200 mg of the protected octapeptide methyl ester (4) was hydrolyzed with NaOH in 
DMF/pyridine as for (2), to give 178 mg of (5). 
(9-desglycinamide) -lysine-vasopressin (dGLVP) (6) 
100 mg of the protected octapeptide (5) was reduced with sodium in liquid ammonia, 
reoxidized, deionized and purified in two steps on Sephadex G-15 as for (3): yield 
20 mg of (6). 
Z-Cys(Bzl)-Tyr(Bzl)-Phe-Gln-Asn-Cys(Bzl)-Pro-Orn(Tos)-OMe (7) 
2.8 g of the protected octapeptide resin was obtained as described above, using 2 g 
of Boc-Orn(Tos)-rer.in containing 0.52 mmol of Boc-Orn(Tos)-OH per g resin. The 
protected octapeptide methjl ester (7) was cleaved from 2.5 g of the resin in the man-
ner detailed above for (1): yield 940 mg of (7). 
Z- Cys (Bzl) - Tyr (Bzl) -Phe-Gln-Asn-Cys (Bzl) -Pro-Orn( Tos )-OH (8) 
400 g of the protected octapeptide methyl ester (7) was hydrolyzed with NaOH in 
DMF/pyridine as for (2), to give 285 mg of (8). 
(9-desglycinamide)-ornithine-vasopressin (dGOVP) (9) 
100 mg of the protected octapeptide (8) was reduced with sodium in liquid ammonia, 
reoxidized, deionized and purified in two steps on Sephadex G-15 as for (3): yield 
22 mg of (9). 
Abbreviations: DMF: Dimethylformamide 
TEA: Triethyl amine 
DCCI: Dicyclohexylcarbodiimide 
TMD: N, N, N', N'-tetramethyl-4, 4' diamino-diphenylmethane 
ACOH: Acetic acid 
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СИНТЕЗ АНАЛОГОВ ДЕСГЛИЦИНАМИДО-ВАСОПРЕССИНА 
М. Тот, Л. Балащпири, Т. Балаж, К. Ковач и Ф. А. Ласло 
Сообщено о синтезе трех аналогов васопрессина в которых С-терминальный глицина-
мидный фрагмент был удален с соответствующего гормона. Все три аналога были синтетизи-
рованы методом реакции в твердой фазе и были очищены двухступенчатой гельфильтрацией. 
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